PDS Biotech publishes Phase 2 VERSATILE-002 results in JAMA Oncology; mOS 39.3 months in ICI-naive HNSCC

PDS Biotechnology Corp

mOS of 39.3 months for CPS≥1 ICI-naive patients vs 17.9 months for pembrolizumab SOC.
ORR 36% vs 19% published for pembro; 13.8% Grade≥3 TRAEs vs 17%.
PIPE financing of up to $22.3M led by Nant Capital; NantWorks gets one-year exclusive license negotiation right for PDS0101.
Company prioritizes PDS0301 in mCRC and pursues partnership for PDS0101.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.